Who are F# PF-004390 Eye Drops's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tiger Balm, Peppermint sweets, SHR8058 eye drops, Angal S, topical spray [Menthol], Placebo with 0.09% menthol gel, Angal, lozenges [menthol],.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/f-pf-004390-eye-drops.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

F# PF-004390 Eye Drops — Competitive Intelligence Brief

F# PF-004390 Eye Drops (F# PF-004390 Eye Drops) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TRPM8 antagonist. Area: Ophthalmology.

phase 3 TRPM8 antagonist TRPM8 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

F# PF-004390 Eye Drops (F# PF-004390 Eye Drops) — Johnson & Johnson Consumer Inc. (J&JCI). PF-004390 is a selective TRPM8 antagonist that blocks cold-sensing ion channels in the eye to reduce ocular pain and discomfort.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
F# PF-004390 Eye Drops TARGET	F# PF-004390 Eye Drops	Johnson & Johnson Consumer Inc. (J&JCI)	phase 3	TRPM8 antagonist	TRPM8
Tiger Balm	Tiger Balm	Apothyx, Co.	marketed	Topical counter-irritant / rubefacient	TRPM8, TRPA1 (transient receptor potential channels)
Peppermint sweets	Peppermint sweets	St. Antonius Hospital	phase 3		TRPM8 receptor
SHR8058 eye drops	SHR8058 eye drops	Jiangsu HengRui Medicine Co., Ltd.	phase 3	TRPM8 channel antagonist	TRPM8
Angal S, topical spray [Menthol]	Angal S, topical spray [Menthol]	Sandoz	phase 3	Topical analgesic/counterirritant	TRPM8 (transient receptor potential melastatin 8)
Placebo with 0.09% menthol gel	Placebo with 0.09% menthol gel	GlaxoSmithKline	phase 3	Topical analgesic/counterirritant	TRPM8 (transient receptor potential melastatin 8)
Angal, lozenges [menthol],	Angal, lozenges [menthol],	Sandoz	phase 3	Topical analgesic/local anesthetic	TRPM8 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TRPM8 antagonist class)

Johnson & Johnson Consumer Inc. (J&JCI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). F# PF-004390 Eye Drops — Competitive Intelligence Brief. https://druglandscape.com/ci/f-pf-004390-eye-drops. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab